First of all great initial results for the treatment of the...

First of all great initial results for the treatment of the disease,
Best wishes to current & future patients using the Oncosil procedure
Also congratulations to management for the work done so far

With no serious adverse safety effects,
The CE Mark awaiting (20 patient safety assessment), shouldn't be to far away
Most likely (1st quarter, 2018)

Also Note :- that the (Oncosil Procedure) will be used as a
(1st-Line Treatment)

Bell potter has a current (DCF modelled valuation) of ($0.41)
They also forecast
(2019 EPS of 5.6 cents)
With a 30 PE = $1.68 for (EOFY/19)

​

	Column 1	Column 2
0	Earnings Forecast
1	June Year End FY16 FY17e FY18e FY19e Revenues 3.8 2.2 5.0 46.3 EBITDA $m -5.0 -7.4 -10.6 29.4 NPAT (underlying) $m -4.8 -6.9 -10.1 29.9 NPAT (reported) $m -4.8 -6.9 -10.1 29.9 EPS underlying (cps) -1.2 -1.4 -1.9 5.6 EPS growth % -46% -17% -38% nm PER (x) nm nm nm nm FCF yield (%) nm nm nm nm EV/EBITDA (x) -7.0 -4.7 -3.3 1.2 Dividend (cps) - - - - Franking 0% 0% 0% 0% Yield % 0.0% 0.0% 0.0% 0.0% ROE % -33.8% -83.5% -67.0% 64.3%